Key safety signals observed in the Phase 2 trial included gastrointestinal adverse effects (nausea, vomiting, diarrhoea, and constipation), increases in resting heart rate, and gallbladder-related events consistent with the broader class of incretin-based therapies
Access to Effective Medications GLP-1 medications have revolutionized obesity management, offering sustainable results beyond diet and exercise alone
Physical inspection provides valuable early warning of potential storage issues
The mechanism likely involves anti-inflammatory effects, improved endothelial function, and direct vascular benefits beyond what weight loss alone would provide
previously reported that glucose toxicity affected severely ovary and endometrium in streptozocin-induced diabetic rats [44]
All trademarks are the property of their respective owners and are used in this article for nominative reference purposes only